2015-2020: Διδάκτωρ Ιατρικής Σχολής Πανεπιστημίου Αθηνών: “Διαταραχές της πήξης και πλασματοκυτταρικές δυσκρασίες” Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή
Moscvin, M. et al. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer Journal, 2023, 13(1), 31
Kastritis, E. et al. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study. American Journal of Hematology, 2023, 98(9), pp. E226–E229
Fotiou D et al. Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies. European Journal of Haematology, 2023, 111(2), pp. 271–278 Ntanasis-Stathopoulos, I. et al. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma. International Journal of Molecular Sciences, 2023, 24(14), 11829.
Theodorakakou, F. et al. Prevalence of MGCS among Patients with Monoclonal Gammopathies. HemaSphere, 2023, 7(6), pp. E908
Makris, N. et al. Cardiac mechanics in response to proteasome inhibition: a prospective study. European Heart Journal Cardiovascular Imaging, 2023, 24(5), pp. 643–652
Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. The Lancet Haematology, 2023, 10(3), pp. e203–e212
Kostopoulos, I.V. et al. Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. Journal of Clinical Oncology, 2023, 41(3), pp. 708–710
Kastritis, E. et al. Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2023
Theodorakakou, F. et al. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy. British Journal of Haematology, 2023
Fotiou, D. et al. Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis. Leukemia and Lymphoma, 2023, 64(6), pp. 1212–1215
Theodorakakou, F. et al. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease. Hematological Oncology, 2023
